{Reference Type}: Journal Article
{Title}: Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: a single-center study of 259 Chinese patients.
{Author}: Xu Y;Shen H;Shi Y;Zhao Y;Zhen X;Sun J;Li X;Zhou ;Yang C;Wang J;Huang X;Wei J;Huang J;Meng H;Yu W;Tong H;Jin J;Xie W;
{Journal}: Front Oncol
{Volume}: 13
{Issue}: 0
{Year}: 2023
{Factor}: 5.738
{DOI}: 10.3389/fonc.2023.1172623
{Abstract}: <B>UNASSIGNED: </B>Diffuse large B-cell lymphoma (DLBCL) is a kind of highly heterogeneous non-Hodgkin lymphoma, both in clinical and genetic terms. DLBCL is admittedly categorized into six subtypes by genetics, which contain MCD, BN2, EZB, N1, ST2, and A53. Dyslipidemia is relevant to a multitude of solid tumors and has recently been reported to be associated with hematologic malignancies. We aim to present a retrospective study investigating dyslipidemia in DLBCL based on the molecular subtypes.<BR><B>UNASSIGNED: </B>This study concluded that 259 patients with newly diagnosed DLBCL and their biopsy specimens were available for molecular typing. Results show that the incidence of dyslipidemia (87.0%, p <0.001) is higher in the EZB subtype than in others, especially hypertriglyceridemia (78.3%, p = 0.001) in the EZB subtype. Based on the pathological gene-sequencing, patients with BCL2 gene fusion mutation are significantly correlative with hyperlipidemia (76.5%, p = 0.006) and hypertriglyceridemia (88.2%, p = 0.002). Nevertheless, the occurrence of dyslipidemia has no remarkable influence on prognosis.<BR><B>UNASSIGNED: </B>In summary, dyslipidemia correlates with genetic heterogeneity in DLBCL without having a significant influence on survival. This research first connects lipids and genetic subtypes in DLBCL.